PureTech Health has appointed Robert Lyne as CEO with immediate effect, after he served as interim chief executive since July 2025.

Lyne said the near-term priority is securing funding for its newest founded entity, Celea Therapeutics, with a deal expected to close in the first half of 2026, after which the company’s operational run rate is expected to reduce significantly.

He also said the company plans to pursue financing for Gallop Oncology in 2026, while moving to a streamlined structure with lower overhead and a more disciplined, capital-efficient investment approach.

Lyne joined PureTech in January 2024 as chief portfolio officer. He is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc.